StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
66
This year
7
Publishing Date
2024 - 01 - 09
1
2024 - 01 - 08
1
2023 - 12 - 15
1
2023 - 12 - 06
1
2023 - 11 - 30
1
2023 - 11 - 28
1
2023 - 11 - 17
1
2023 - 10 - 20
1
2023 - 10 - 12
1
2023 - 09 - 12
1
2023 - 08 - 23
1
2023 - 08 - 17
1
2023 - 07 - 31
1
2023 - 06 - 27
1
2023 - 05 - 25
1
2023 - 05 - 08
1
2023 - 04 - 29
1
2023 - 04 - 14
1
2023 - 03 - 27
1
2023 - 03 - 16
1
2023 - 03 - 13
1
2022 - 12 - 30
1
2022 - 12 - 09
1
2022 - 09 - 13
1
2022 - 08 - 03
1
2022 - 06 - 27
1
2022 - 06 - 06
1
2022 - 06 - 03
1
2022 - 05 - 12
1
2022 - 03 - 23
1
2022 - 01 - 19
1
2022 - 01 - 14
1
2021 - 12 - 10
1
2021 - 11 - 19
1
2021 - 11 - 17
1
2021 - 09 - 28
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 09 - 07
1
2021 - 08 - 05
2
2021 - 07 - 09
1
2021 - 06 - 24
1
2021 - 06 - 23
1
2021 - 05 - 28
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 05
1
2021 - 05 - 04
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 16
1
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 04 - 07
1
2021 - 03 - 26
1
2021 - 03 - 25
1
2021 - 03 - 10
1
2021 - 02 - 08
1
2020 - 12 - 28
1
Sector
Commercial services
1
Distribution services
1
Electronic technology
1
Health technology
66
Manufacturing
11
N/a
1
Tags
Acquisition
9
Active
10
Antiviral
10
Application
24
Approval
31
Authorization
14
Breast
12
Cancer
66
Candidate
16
Children
18
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
15
Collaboration
21
Comirnaty®
10
Conference
18
Covid
58
Covid-19
41
Disease
28
Drug
54
Earnings
20
Ema
10
Emergency use authorization
10
Europe
13
Events
12
Expected
10
Fda
74
Fda-approvals
14
Financial
19
Global
56
Growth
29
Hiv
15
Hormone
10
License
19
Market
100
Merge
15
N/a
432
Order
15
People
24
Pharm-country
34
Pharmaceutical
17
Phase 2
12
Phase 3
21
Positive
45
Potential
11
Product-news
10
Regulatory
12
Report
49
Research
51
Respiratory
10
Results
62
Risk
16
Study
20
Therapeutics
40
Therapy
29
Topline
14
Treatment
74
Trial
47
Ulcerative colitis
12
Update
14
Vaccine
106
Entities
Abbott laboratories
2
Abbvie inc.
10
Adaptimmune therapeutics plc
1
Adc therapeutics sa
5
Advaxis, inc.
1
Agilent technologies, inc.
1
Agios pharmaceuticals, inc.
10
Alnylam pharmaceuticals, inc.
10
Amgen inc.
10
Aptorum group limited
1
Arvinas, inc.
8
Astellas pharma inc
11
Astrazeneca plc
10
Aveo pharmaceuticals, inc.
10
Becton, dickinson and company
1
Beigene, ltd.
10
Biontech se
1
Blueprint medicines corporation
10
Bristol-myers squibb company
19
Cel-sci corporation
1
Celcuity inc.
1
Clovis oncology, inc.
11
Cts corporation
1
Eli lilly and company
18
Epizyme, inc.
10
Exelixis, inc.
12
Genmab a/s
2
Gilead sciences, inc.
2
Glaxosmithkline plc
8
Hologic, inc.
1
Illumina, inc.
11
Immunogen, inc.
1
Incyte corporation
12
Innate pharma sa
1
Johnson & johnson
4
Karyopharm therapeutics inc.
10
Kura oncology, inc.
1
Macrogenics, inc.
1
Merck & company, inc.
1
Myriad genetics, inc.
1
Neurocrine biosciences, inc.
1
Novartis ag
9
Oncolytics biotech inc.
2
Pfizer, inc.
66
Regeneron pharmaceuticals, inc.
10
Replimune group, inc.
1
Rigel pharmaceuticals, inc.
10
Sanofi
16
Seagen inc.
2
Sensient technologies corporation
1
Spectrum pharmaceuticals, inc.
1
Takeda pharmaceutical company limited
3
Teva pharmaceutical industries ltd
1
Trinity biotech plc
1
Verastem, inc.
10
Y-mabs therapeutics, inc.
10
Symbols
A
27
ABBV
53
ABT
49
ALPMF
50
ALPMY
50
AMGN
91
ANIX
49
ARAY
26
AVEO
24
AZN
144
AZNCF
74
BCTX
50
BDX
26
BGNE
59
BIOC
31
BMY
107
BPMC
27
CLVS
33
CSTL
28
EXAS
56
EXEL
43
FNCTF
138
GH
54
GILD
59
GLAXF
46
GNPX
26
GSK
54
GTHX
27
HOLX
32
HOTH
29
IBRX
30
ILMN
68
IMGN
25
IMMP
34
INCY
57
JAGX
37
JNJ
139
KPTI
27
LLY
139
LTRN
25
MRK
75
MRTX
32
MYGN
50
NTRA
38
NVCR
31
NVS
106
NVSEF
91
NVTA
25
ONCY
41
PDSB
35
PFE
66
QGEN
31
REGN
42
SGEN
55
SNY
217
SNYNF
167
TAK
35
TMO
51
VCYT
46
VSTM
25
Exchanges
Amex
1
Nasdaq
49
Nyse
66
Crawled Date
2024 - 01 - 09
1
2024 - 01 - 08
1
2023 - 12 - 15
1
2023 - 12 - 06
1
2023 - 11 - 30
1
2023 - 11 - 28
1
2023 - 11 - 17
1
2023 - 10 - 20
1
2023 - 10 - 12
1
2023 - 09 - 13
1
2023 - 08 - 23
1
2023 - 08 - 17
1
2023 - 07 - 31
1
2023 - 06 - 27
1
2023 - 05 - 25
1
2023 - 05 - 08
1
2023 - 04 - 29
1
2023 - 04 - 14
1
2023 - 03 - 27
1
2023 - 03 - 17
1
2023 - 03 - 13
1
2022 - 12 - 30
1
2022 - 12 - 09
1
2022 - 09 - 13
1
2022 - 08 - 03
1
2022 - 06 - 27
1
2022 - 06 - 06
1
2022 - 06 - 03
1
2022 - 05 - 12
1
2022 - 03 - 23
1
2022 - 01 - 19
1
2022 - 01 - 14
1
2021 - 12 - 10
1
2021 - 11 - 19
1
2021 - 11 - 17
1
2021 - 09 - 28
1
2021 - 09 - 20
1
2021 - 09 - 17
1
2021 - 09 - 07
1
2021 - 08 - 05
2
2021 - 07 - 09
1
2021 - 06 - 24
1
2021 - 06 - 23
1
2021 - 05 - 28
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 05
1
2021 - 05 - 04
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 16
1
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 04 - 07
1
2021 - 03 - 26
1
2021 - 03 - 25
1
2021 - 03 - 10
1
2021 - 02 - 08
1
2020 - 12 - 28
1
Crawled Time
00:00
2
01:00
2
02:00
2
04:00
2
05:00
1
06:00
2
06:03
1
07:00
2
10:00
1
11:00
3
12:00
8
13:00
1
13:15
1
13:20
1
13:30
1
13:50
1
14:00
1
14:20
1
15:00
2
15:15
1
16:00
4
16:20
1
17:00
4
17:37
1
18:00
2
18:04
1
18:26
1
18:31
2
18:33
1
18:40
1
18:42
1
19:00
1
20:59
1
21:00
3
22:00
5
23:00
1
Source
www.biospace.com
16
www.fda.gov
10
www.globenewswire.com
13
www.prnewswire.com
27
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Cancer
symbols :
Pfe
save search
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published:
2024-02-14
(Crawled : 14:00)
- biospace.com/
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-2.41%
|
O:
0.15%
H:
0.59%
C:
0.37%
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
|
-28.83%
|
O:
-1.09%
H:
5.61%
C:
4.49%
first
breast
cancer
trial
therapeutics
advanced
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published:
2024-02-06
(Crawled : 12:00)
- globenewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-0.94%
|
O:
0.34%
H:
3.99%
C:
3.15%
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
|
-26.57%
|
O:
0.91%
H:
5.05%
C:
4.9%
arv-471
fda
breast
cancer
treatment
designation
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Published:
2024-02-02
(Crawled : 12:00)
- globenewswire.com
GNMSF
|
News
|
$290.34
3.83%
340
|
Health Technology
|
3.4%
|
O:
-0.78%
H:
0.3%
C:
-0.84%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-3.55%
|
O:
-0.4%
H:
0.07%
C:
-0.92%
GMAB
|
News
|
$28.47
-0.32%
-0.32%
460K
|
Health Technology
|
1.38%
|
O:
-1.21%
H:
0.72%
C:
-0.11%
authorization
cancer
treatment
application
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published:
2024-01-31
(Crawled : 02:00)
- prnewswire.com
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
-17.75%
|
O:
4.34%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-17.98%
|
O:
0.0%
H:
1.38%
C:
0.26%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-2.59%
|
O:
0.56%
H:
1.25%
C:
-0.33%
keytruda
drug
japan
bladder
cancer
treatment
application
advanced
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published:
2024-01-26
(Crawled : 17:00)
- prnewswire.com
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
-21.29%
|
O:
-6.38%
H:
0.88%
C:
0.88%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-17.05%
|
O:
0.09%
H:
0.17%
C:
-0.3%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-4.19%
|
O:
0.58%
H:
1.01%
C:
-0.58%
keytruda
bladder
cancer
treatment
application
advanced
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published:
2024-01-09
(Crawled : 12:00)
- globenewswire.com
GNMSF
|
News
|
$290.34
3.83%
340
|
Health Technology
|
-13.16%
|
O:
-3.69%
H:
1.71%
C:
-2.41%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-11.02%
|
O:
0.07%
H:
0.88%
C:
-0.68%
GMAB
|
News
|
$28.47
-0.32%
-0.32%
460K
|
Health Technology
|
-12.85%
|
O:
-1.1%
H:
0.46%
C:
-0.06%
tivdak
drug
license
review
food
cancer
application
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
Published:
2024-01-08
(Crawled : 18:00)
- biospace.com/
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-10.69%
|
O:
-0.37%
H:
1.09%
C:
0.75%
talzenna
cancer
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published:
2023-12-15
(Crawled : 22:00)
- prnewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
Email alert
Add to watchlist
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
Email alert
Add to watchlist
padcev
fda
first
approved
bladder
cancer
treat
advanced
plus
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Published:
2023-12-06
(Crawled : 04:00)
- globenewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-9.52%
|
O:
0.0%
H:
1.07%
C:
-1.03%
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
|
46.74%
|
O:
5.35%
H:
26.96%
C:
24.13%
arv-471
conference
breast
symposium
cancer
program
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published:
2023-11-30
(Crawled : 22:00)
- prnewswire.com
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
-19.29%
|
O:
3.87%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-21.96%
|
O:
-3.37%
H:
4.51%
C:
4.51%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-13.62%
|
O:
-4.92%
H:
1.48%
C:
-0.21%
padcev
fda
license
review
bladder
cancer
treatment
application
grants
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Published:
2023-11-28
(Crawled : 22:00)
- globenewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-11.35%
|
O:
0.27%
H:
1.51%
C:
1.04%
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
|
39.23%
|
O:
1.72%
H:
4.07%
C:
0.6%
arv-471
breast
symposium
cancer
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published:
2023-11-17
(Crawled : 04:00)
- prnewswire.com
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
-18.1%
|
O:
0.04%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-17.98%
|
O:
1.38%
H:
1.79%
C:
1.79%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-11.59%
|
O:
0.5%
H:
0.3%
C:
0.0%
xtandi
fda
approved
cancer
treatment
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Published:
2023-10-20
(Crawled : 10:00)
- globenewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-15.61%
|
O:
-0.42%
H:
0.16%
C:
-1.32%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
4.46%
|
O:
0.6%
H:
0.61%
C:
-0.56%
kisqali
breast
cancer
risk
novartis
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Published:
2023-10-12
(Crawled : 12:00)
- biospace.com/
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-20.51%
|
O:
0.0%
H:
0.33%
C:
-0.57%
braftovi
fda
lung
cancer
cell
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published:
2023-09-12
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-36.22%
|
O:
-0.03%
H:
1.04%
C:
-0.37%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-22.93%
|
O:
0.18%
H:
1.2%
C:
-0.38%
xtandi
cancer
treatment
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published:
2023-08-23
(Crawled : 12:00)
- biospace.com/
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-37.77%
|
O:
0.59%
H:
0.46%
C:
0.46%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-28.56%
|
O:
0.68%
H:
0.11%
C:
-1.16%
xtandi
fda
review
cancer
grants
TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology
Published:
2023-08-17
(Crawled : 17:00)
- biospace.com/
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-25.82%
|
O:
0.34%
H:
3.15%
C:
2.56%
cancer
therapeutics
platform
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Published:
2023-07-31
(Crawled : 21:00)
- globenewswire.com
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-27.08%
|
O:
-0.48%
H:
0.0%
C:
0.0%
ARVN
|
$32.51
-4.38%
-4.58%
470K
|
Health Technology
|
37.54%
|
O:
-0.73%
H:
2.32%
C:
1.3%
protac
breast
innovation
cancer
group
designation
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published:
2023-06-27
(Crawled : 01:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
7.57%
|
O:
-1.1%
H:
0.0%
C:
0.0%
TAK
|
News
|
$13.23
-1.12%
0.0%
920K
|
Health Technology
|
-15.38%
|
O:
-0.95%
H:
0.19%
C:
-0.32%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-28.65%
|
O:
0.19%
H:
0.11%
C:
-1.46%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
-0.65%
|
O:
-0.01%
H:
0.16%
C:
-0.32%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-8.54%
|
O:
0.03%
H:
0.12%
C:
-0.24%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
13.7%
|
O:
-0.91%
H:
0.56%
C:
-0.5%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
63.23%
|
O:
2.15%
H:
1.18%
C:
0.43%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-24.39%
|
O:
-0.06%
H:
0.46%
C:
0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
-1.23%
|
O:
-0.21%
H:
0.42%
C:
0.13%
report
business
cancer
treat
global
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Published:
2023-05-25
(Crawled : 21:00)
- prnewswire.com
ALPMF
|
News
|
$9.5
43.47%
1.2K
|
Health Technology
|
-43.95%
|
O:
-1.8%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-43.46%
|
O:
-1.4%
H:
0.3%
C:
0.01%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-30.43%
|
O:
0.56%
H:
1.05%
C:
-1.16%
asco
cancer
pipeline
meeting
← Previous
1
2
3
4
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.